参考文献/References:
[1] Chiang CE,Okumura K,Zhang S,et al. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation[J]. J Arrhythm,2017,33(4):345-367.
[2] Wijesurendra RS,Casadei B. Mechanisms of atrial fibrillation[J]. Heart,2019,105(24):1860-1867.
[3] Qin M,Zeng C,Liu X. The cardiac autonomic nervous system:a target for modulation of atrial fibrillation[J]. Clin Cardiol,2019,42(6):644-652.
[4] Pellman J,Sheikh F. Atrial fibrillation:mechanisms,therapeutics,and future directions[J]. Compr Physiol,2015,5(2):649-665.
[5] Lee HC,Huang KTL,Wang XL,et al. Autoantibodies and cardiac arrhythmias[J]. Heart Rhythm,2011,8(11):1788-1795.
[6] Yalcin MU,Gurses KM,Kocyigit D,et al. Cardiac autoantibody levels predict recurrence following cryoballoon-based pulmonary vein isolation in paroxysmal atrial fibrillation patients [J]. J Cardiovasc Electrophysiol,2015,26(6):615-621.
[7] Gawa?ko M,Balsam P,Lodz iński P,et al. Cardiac arrhythmias in autoimmune diseases[J]. Circ J,2020,84(5):685-694.
[8] 朱静文,蒋桔泉. 迷走神经干预在心血管疾病中的治疗作用[J]. 心血管病学进展,2020,41(3):301-305.
[9] Choi EK,Zhao Y,Everett 4th T H,et al. Ganglionated plexi as neuromodulation targets for atrial fibrillation[J]. J Cardiovasc Electrophysiol,2017,28(12):1485-1491.
[10] Ma G,Wu X,Zeng L,et al. Association of autoantibodies against M2-muscarinic acetylcholine receptor with atrial fibrosis in atrial fibrillation patients[J]. Cardiol Res Pract,2019,2019:8271871.
[11] Hong CM,Zheng QS,Liu XT,et al. Effects of autoantibodies against M2 muscarinic acetylcholine receptors on rabbit atria in vivo[J]. Cardiology,2009,112(3):180-187.
[12] Park HW,Shen MJ,Lin SF,et al. Neural mechanisms of atrial fibrillation[J]. Curr Opin Cardiol,2012,27(1):24-28.
[13] Galloway A,Li H,Vanderlinde-Wood M,et al. Activating autoantibodies to the beta1/2-adrenergic and M2 muscarinic receptors associate with atrial tachyarrhythmias in patients with hyperthyroidism[J]. Endocrine,2015,49(2):457-463.
[14] Li H,Murphy T,Zhang L,et al. β 1-adrenergic and M2 muscarinic autoantibodies and thyroid hormone facilitate induction of atrial fibrillation in male rabbi ts[J]. Endocrinology,2016,157(1):16-22.
[15] Stavrakis S,Yu X,Patterson E,et al. Activating autoantibodies to the beta-1 adrenergic and m2 muscarinic receptors facilitate atrial fibrillation in patients with Graves’ hyperthyroidism[J]. J Am Coll Cardiol,2009,54(14):1309-1316.
[16] Li H,Scherlag BJ,Kem DC,et al. Inducible cardiac arrhythmias caused by enhanced beta1-adrenergic autoantibody expression in the rabbit[J]. Am J Physiol Heart Circ Physiol,2014,306(3):H422-H428.
[17] Jiménez MAV,Nascimento JHM,Monnerat G,et al. Autoantibodies with beta-adrenergic activity from chronic chagasic patients induce cardiac arrhythmias and early afterdepolarization in a drug-induced LQT2 rabbit hearts[J]. Int J Cardiol,2017,240:354-359.
[18] Shang L,Zhang L,Shao M,et al. Elevated β1-adrenergic receptor autoantibody levels increase atrial fibrillation susceptibility by promoting atrial fibrosis [J]. Front Physiol,2020,11:76.
[19] Yalcin MU,Gurses KM,Kocyigit D,et al. Elevated M2-muscarinic and beta1-adrenergic receptor autoantibody levels are associated with paroxysmal atrial fibrillation [J]. Clin Res Cardiol, 2015,104(3):226-233.
[20] 邵梦娇,张玲,商鲁翔,等. β1肾上腺素能受体自身抗体表达增强对心房颤动及心房电重构的影响?[J]. 中国心脏起搏与心电生理杂志,2019,33(2):50-54.
[21] Gurses KM,Yalcin MU,Kocyigit D,et al. M2-muscarinic acetylcholine receptor autoantibody levels predict left atrial fibrosis severity in paroxysmal lone atrial fibrillation patients undergoing cryoablation[J]. Europace,2015,17(2):239-246.
[22] Lv T,Du Y,Cao N,et al. Proliferation in cardiac fibroblasts induced by beta1-adrenoceptor autoantibody and the underlying mechanisms[J]. Sci Rep,2016,6:32430.
[23] Zou C,Zhang Z,Zhao W,et al. Predictive value of pre-procedural autoantibodies against M2-muscarinic acetylcholine receptor for recurrence of atrial fibrillation one year after radiofrequency catheter ablation[J]. J Transl Med,2013,11:7.
[24] Li H,Zhang L,Huang B,et al. A peptidomimetic inhibitor suppresses the inducibility of β1-adrenergic autoantibody-mediated cardiac arrhythmias in the rabbit[J]. J Interv Card Electrophysiol,2015,44(3):205-212.
[25] Miller AJ,Doherty TA. Hop to it:the first animal model of autoimmune postural orthostatic tachycardia syndrome[J]. J Am Heart Assoc,2019,8(19):e014084.
[26] Yoshikawa T,Baba A,Akaishi M,et al. Immunoadsorption therapy for dilated cardiomyopathy using tryptophan column—A prospective,multicenter,randomized,within-patient and parallel-group comparative study to evaluate efficacy and safety[J]. J Clin Apher,2016,31(6):535-544.
[27] Shaw BH,Stiles LE,Bourne K,et al. The face of postural tachycardia syndrome—insights from a large cross-sectional online community-based survey[J]. J Intern Med,2019,286(4):438-448.
[28] Fedorowski A,Li H,Yu X,et al. Antiadrenergic autoimmunity in postural tachycardia syndrome[J]. Europace,2017,19(7):1211-1219.
[29] Schofield JR,Chemali KR. Intravenous immunoglobulin therapy in refractory autoimmune dysautonomias:a retrospective analysis of 38 patients[J]. Am J Ther,2019,26(5):570-582.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(3):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(3):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(3):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(3):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(3):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]